Medication Fact Sheets
|
March 3, 2025

Nortriptyline: How It Works, Benefits, and Potential Risks

Written By
Dr. Jaime Cloyd ND
Medically Reviewed by
Updated On
March 4, 2025

Depression is a significant mental health concern in the United States, affecting an estimated 25 million adults and teens every year. Antidepressants have been shown to help many individuals manage depressive symptoms, improving the quality of life for those who respond to them.

One class of antidepressants, known as tricyclic antidepressants (TCAs), has been used for decades to treat depression. These medications, which include well-known options like nortriptyline, work by influencing neurotransmitters in the brain to alleviate mood symptoms. 

This article provides a comprehensive guide to understanding nortriptyline, its uses, benefits, risks, and proper administration to ensure its safe and effective use in treating depression and other conditions.

[signup]

Understanding Nortriptyline

Nortriptyline belongs to a class of medications called tricyclic antidepressants (TCAs), which have received the U.S. Food and Drug Administration's (FDA) approval for treating major depressive disorder (MDD). Nortriptyline was approved in 1964.

How Nortriptyline Works in the Body

Neurotransmitters are chemical messengers the nervous system uses to send signals between nerve cells. They influence many physiological functions, including mood, pain perception, and stress responses. 

Theories suggest that deficiencies in neurotransmitters underlie the psychopathological basis of depression and chronic pain. Antidepressant medications broadly function to increase neurotransmitter levels to alleviate symptoms associated with these conditions.

Specifically, TCAs modulate neurotransmitter systems by inhibiting the reuptake of norepinephrine and serotonin into nerve cells, increasing their availability in the brain. 

Based on their chemical structure, TCAs are further classified as secondary or tertiary amines. Nortriptyline is a secondary amine, which means it preferentially blocks the reuptake of norepinephrine over serotonin. 

Additionally, TCAs modulate three other neurotransmitter systems by inhibiting the activity of histamine, 5-hydroxytryptamine, and acetylcholine.

Uses of Nortriptyline

Currently, the only FDA-approved indication for nortriptyline is the treatment of MDD in adolescents and adults. 

MDD is a mood disorder characterized by persistent feelings of sadness, hopelessness, and a loss of interest or pleasure in most daily activities, lasting for at least two weeks. It can affect various aspects of life, including sleep, appetite, energy levels, and concentration, and may lead to significant emotional and physical impairment.

However, research has demonstrated that using TCAs to treat other medical conditions can lead to positive clinical outcomes. Therefore, doctors may also prescribe nortriptyline off-label to treat:

Benefits and Efficacy

Nortriptyline increases the availability of norepinephrine and serotonin in the brain. A PET scan study showed that nortriptyline works by blocking about 50-70% of norepinephrine transporters in the brain when taken in doses between 75-200 mg per day. The most effective dose was found to be around 65.9 mg per day, which led to a noticeable improvement in depressive symptoms.

Studies have evaluated nortriptyline's efficacy in treating MDD in different populations and settings:

  • Bereavement-Related Major Depression: A controlled study found that nortriptyline was superior to placebo in achieving remission of bereavement-related major depressive episodes, with a remission rate of 56% for nortriptyline alone.
  • Parkinson's Disease: Nortriptyline was found to be superior to placebo and paroxetine in treating depression in patients with Parkinson's disease, with a response rate of 53%.
  • Elderly Patients: In elderly patients with recurrent major depression, a combination of nortriptyline and interpersonal psychotherapy resulted in a high remission rate of 78.7%.
  • Treatment-Resistant Depression: In patients with treatment-resistant major depression, approximately 40% responded to nortriptyline, and 12% achieved remission after 6 weeks of treatment.

Nortriptyline reduces neuropathic pain in multiple ways. In addition to inhibiting neurotransmitter reuptake in the central nervous system, its ability to activate beta-2-adrenoceptors and delta-opioid receptors in the peripheral nervous system contributes to its pain-relieving effects.

A systematic review and meta-analysis recently published in 2024 concluded that nortriptyline significantly reduced pain severity in various pain conditions, including chronic low back pain, painful symptoms in MDD, neuropathies, and chronic pelvic pain.

Potential Risks and Side Effects

While TCAs are effective, they are more likely to cause more side effects compared to other types of antidepressants. According to one clinical trial, 38.1% of patients who were given nortriptyline for neuropathy discontinued the drug due to adverse effects. 

Common Side Effects

The most common side effects associated with nortriptyline include:

Black Box Warning

Nortriptyline carries a black box warning regarding the increased risk of suicidal thoughts and behaviors, particularly in children, adolescents, and young adults. Short-term studies have not shown an increased risk of suicidality in adults over 24 years old and have demonstrated a risk reduction for suicidality and suicidal behavior in adults aged 65 and older. 

This risk necessitates careful consideration of the clinical need versus the potential risk when prescribing nortriptyline. All patients starting on antidepressant therapy should be closely monitored for clinical worsening, suicidality, or unusual changes in behavior.

Long-Term Risks

Over time, especially at higher doses, there can be an increased risk of developing antidepressant discontinuation syndrome. Abrupt discontinuation of the medication can cause withdrawal symptoms, including anxiety, insomnia, irritability, and flu-like symptoms. This reaction is unrelated to addiction, but rather nortriptyline's effects on neurotransmitter systems, which can lead to challenges when attempting to stop the medication. 

Never suddenly discontinue nortriptyline without consulting your healthcare provider. Discontinuation of the medication should always be done under the guidance and care of your healthcare provider, who can work with you to develop a tapering strategy that minimizes the risk of withdrawal symptoms.

Nortriptyline can have more severe adverse effects, including: 

  • Orthostatic hypotension (a significant drop in blood pressure when standing from a sitting or lying position)
  • High blood pressure
  • Loss of consciousness
  • Arrhythmias
  • Heart attack 
  • Stroke
  • Paralytic ileus (paralysis of the intestinal muscles that prevents the movement of food and waste through the digestive tract) 
  • Glaucoma
  • Low white blood cell counts
  • Hepatitis
  • Angioedema (swelling of the deep layers of the skin)
  • Seizures
  • Hallucinations
  • Movement disorders

Dosage and Administration

Nortriptyline is available in 10 mg, 25 mg, 50 mg, and 75 mg capsules. General dosing recommendations are provided below:

  • Adults: 25 mg three or four times daily. Begin at a low dose and increase gradually as required. The total daily dosage may be given once daily. When doses above 100 mg daily are taken, nortriptyline plasma levels should be monitored and maintained within 50 to 150 ng/mL. It is not recommended to take more than 150 mg daily. 
  • Adolescents and Elderly: 30 to 50 mg daily, either given in divided doses or once daily

Consult your healthcare provider to determine the appropriate dosage, which will depend on individual factors such as age, health condition, and response to treatment. Always follow your doctor's instructions and never change your dosage without consulting them first. 

Tips for Safe Administration

Nortriptyline can be taken with or without food.

Higher doses can be taken at night before bed to mitigate drowsiness that may occur.

Take your medication as prescribed, and do not abruptly stop without consulting your doctor.

It is best to avoid alcohol when taking nortriptyline. This combination increases the risk of serious side effects, including a higher risk of suicidal thoughts or overdose and reduced tolerance to alcohol.

Additionally, nortriptyline can interact with other medications, increasing the risk of adverse effects. Do not take nortriptyline with the following medications without talking to your doctor:

  • Serotonin-enhancing drugs and supplements, including other TCAs, triptans, selective serotonin reuptake inhibitors (SSRIs), tramadol, fentanyl, lithium, buspirone, tryptophan, and St. John's wort
  • Monoamine oxide inhibitors (MAOIs) 
  • Drugs that inhibit cytochrome P4502D6, such as quinidine and cimetidine

This list does not include all possible drug interactions. Always give your doctor a complete list of medications and supplements you are taking before starting nortriptyline to avoid adverse reactions. 

Alternatives and Comparisons

Other antidepressants and non-pharmacological interventions may offer similar benefits for managing mood and disorders.

Antidepressants

Alternative antidepressants to TCAs include SSRIs, serotonin-norepinephrine reuptake inhibitors (SNRIs), and atypical antidepressants.

SSRIs, such as fluoxetine, sertraline, and escitalopram, are commonly used as first-line treatments due to their favorable side effect profiles compared to TCAs. SSRIs are generally better tolerated and have fewer anticholinergic and cardiovascular side effects.

SNRIs, including venlafaxine and duloxetine, are also effective alternatives. Venlafaxine has shown greater efficacy than SSRIs in some studies, particularly in treatment-resistant depression. Duloxetine is noted for its effectiveness in treating depression and coexisting pain conditions.

Antidepressant therapy is often selected based on the side effect profiles of different medications, as patients may respond better to certain drugs depending on their tolerance to specific side effects. For example:

  • Bupropion is a norepinephrine-dopamine reuptake inhibitor that has a lower incidence of sexual dysfunction, weight gain, and sedation.
  • Mirtazapine may be a well-suited option for patients with insomnia or significant weight loss due to its sedative and appetite-stimulating properties.

Non-Medication Options

A personalized multimodal approach that integrates physical activity, stress management, sleep optimization, and nutritional factors has been recommended for managing chronic pain and depression

Psychotherapy can be an effective treatment for both depression and pain disorders, as it helps individuals address the underlying psychological factors contributing to their symptoms. Cognitive behavioral therapy (CBT), in particular, is commonly used to help patients identify and change negative thought patterns, develop healthier coping strategies, and improve emotional regulation.

Acceptance and commitment therapy (ACT) and mindfulness-based interventions (MBIs) are additional types of evidence-based psychotherapies that are effective in treating depression and pain disorders. 

Addressing Misconceptions

Is Nortriptyline Addictive?

Nortriptyline is not considered to be psychologically addicting. However, sudden discontinuation after long-term use can lead to antidepressant discontinuation syndrome, which can cause uncomfortable withdrawal symptoms.

Can Anyone Take Nortriptyline?

Nortriptyline may not be suitable for all individuals due to age, pre-existing health conditions, or the concomitant use of other medications. Always consult a healthcare provider to determine if nortriptyline is a safe and appropriate option for you.

[signup]

Conclusion

  • Nortriptyline is a tricyclic antidepressant with FDA approval to treat major depressive disorder. Doctors may also prescribe nortriptyline off-label as part of a strategy to manage chronic neuropathic pain disorders, prevent migraine headaches, and help patients quit smoking.
  • Nortriptyline is effective in treating both depression and certain types of chronic pain, with clinical evidence showing comparable results to other antidepressants.
  • Compared to newer antidepressants, nortriptyline has a broader range of side effects. Its safety profile may make it a less desirable or tolerated option, especially for those with sensitivity to anticholinergic effects or those at risk of cardiovascular problems.
  • The use of nortriptyline for managing depression and chronic pain should always be done under the supervision of a licensed healthcare professional. A doctor can ensure the correct dosing, monitor for side effects, and adjust treatment as needed to balance efficacy with safety.
The information in this article is designed for educational purposes only and is not intended to be a substitute for informed medical advice or care. This information should not be used to diagnose or treat any health problems or illnesses without consulting a doctor. Consult with a health care practitioner before relying on any information in this article or on this website.

Learn more

No items found.

Lab Tests in This Article

No lab tests!
  1. Anderson, I. M. (1998). SSRIs versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depression and Anxiety, 7 Suppl 1, 11–17. https://pubmed.ncbi.nlm.nih.gov/9597346/
  2. Anderson, S. (2022, May 19). 6 Preventable Risk Factors Associated With Heart Attacks. Rupa Health. https://www.rupahealth.com/post/5-things-to-do-after-a-heart-attack
  3. Barohn, R. J., Pasnoor, M., Brown, A. C., et al. (2021). Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS). JAMA Neurology, 78(1), 68–68. https://doi.org/10.1001/jamaneurol.2020.2590
  4. Bauer, M., Tharmanathan, P., Volz, H.-P., et al. (2009). The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression. European Archives of Psychiatry and Clinical Neuroscience, 259(3), 172–185. https://doi.org/10.1007/s00406-008-0849-0
  5. Benbouzid, M., Choucair-Jaafar, N., Yalcin, I., et al. (2008). Chronic, but not acute, tricyclic antidepressant treatment alleviates neuropathic allodynia after sciatic nerve cuffing in mice. European Journal of Pain, 12(8), 1008–1017. https://doi.org/10.1016/j.ejpain.2008.01.010
  6. Bohren, Y., Tessier, L.-H., Megat, S., et al. (2013). Antidepressants suppress neuropathic pain by a peripheral β2-adrenoceptor mediated anti-TNFα mechanism. Neurobiology of Disease, 60, 39–50. https://doi.org/10.1016/j.nbd.2013.08.012
  7. Bryant, A. (2024, December 13). Antidepressants 101: Benefits, Risks, and How They Work. Rupa Health. https://www.rupahealth.com/post/antidepressants-101-benefits-risks-and-how-they-work
  8. Cloyd, J. (2023, April 14). A Functional Medicine Glaucoma Protocol. Rupa Health. https://www.rupahealth.com/post/a-functional-medicine-glaucoma-protocol
  9. Cloyd, J. (2023, September 8). Top Labs To Run Bi-Annually On Your Patients Who Suffer From Hepatitis. Rupa Health. https://www.rupahealth.com/post/top-labs-to-run-bi-annually-on-your-patients-who-suffer-from-hepatitis
  10. Cloyd, J. (2023, October 9). Rhythms of the Heart: Demystifying Common Types of Heart Arrhythmia. Rupa Health. https://www.rupahealth.com/post/rhythms-of-the-heart-demystifying-common-types-of-heart-arrhythmia
  11. Cloyd, J. (2023, December 1). A Functional Medicine Protocol For Balancing Blood Sugar. Rupa Health. https://www.rupahealth.com/post/a-functional-medicine-protocol-for-balancing-blood-sugar
  12. Cloyd, J. (2024, June 20). Understanding Heart Palpitations: Causes, Diagnosis, and Treatment. Rupa Health. https://www.rupahealth.com/post/understanding-heart-palpitations-causes-diagnosis-and-treatment
  13. Cloyd, J. (2024, November 27). Duloxetine: Uses, Benefits, and Side Effects Explained. Rupa Health. https://www.rupahealth.com/post/duloxetine-uses-benefits-and-side-effects-explained
  14. Cox, A. D. (2022, September 19). Trigeminal Neuralgia: Causes, Triggers, and Treatments. Rupa Health. https://www.rupahealth.com/post/trigeminal-neuralgia
  15. Creedon, K. (2022, July 14). Simple lifestyle changes that can help keep high blood pressure under control. Rupa Health. https://www.rupahealth.com/post/simple-lifestyle-changes-that-can-help-control-high-blood-pressure
  16. Creedon, K. (2022, August 4). 6 speciality labs that get to the root cause of insomnia. Www.rupahealth.com. https://www.rupahealth.com/post/6-speciality-labs-that-get-to-the-root-cause-of-insomnia
  17. Daglis, S. (2024, August 7). Tachycardia: Don't Let Your Heart Run Away with You. Rupa Health. https://www.rupahealth.com/post/tachycardia-dont-let-your-heart-run-away-with-you
  18. de Jong, M., Peeters, F., Gard, T., et al. (2018). A Randomized Controlled Pilot Study on Mindfulness-Based Cognitive Therapy for Unipolar Depression in Patients With Chronic Pain. The Journal of Clinical Psychiatry, 79(1), 26–34. https://doi.org/10.4088/jcp.15m10160
  19. Derry, S., Wiffen, P. J., Aldington, D., et al. (2015). Nortriptyline for neuropathic pain in adults. Cochrane Database of Systematic Reviews, 2015(1), CD011209. https://doi.org/10.1002/14651858.cd011209.pub2
  20. Diorio, B. (2022, August 11). Anxiety, GI Discomfort, Irritability, And Poor Memory Are All Signs Of These Neurotransmitter Imbalances. Rupa Health. https://www.rupahealth.com/post/a-functional-medicine-approach-to-understanding-neurotransmitters-101
  21. Diorio, B. (2022, September 6). How to increase your serotonin levels naturally. Rupa Health. https://www.rupahealth.com/post/how-to-increase-your-serotonin-naturally
  22. Diorio, B. (2022, October 25). How to Balance Adrenaline Levels Naturally. Rupa Health. https://www.rupahealth.com/post/adrenaline
  23. Diorio, B. (2022, November 3). Brain Fog, Muscles Weakness, and Constipation are Symptoms That This Neurotransmitter Could Be Low. Rupa Health. https://www.rupahealth.com/post/poor-short-term-memory-muscles-weakness-and-constipation-are-symptoms-of-low-levels-of-this-neurotransmitter
  24. Gabriel, M., & Sharma, V. (2017). Antidepressant discontinuation syndrome. Canadian Medical Association Journal, 189(21), E747–E747. https://doi.org/10.1503/cmaj.160991
  25. Gerow, S. (2024, October 23). If Your Patient is a Young Adult with Seizures, Run These Lab Tests. Rupa Health. https://www.rupahealth.com/post/if-your-patient-is-a-young-adult-with-seizures-run-these-lab-tests
  26. Gómez-Pérez, F. J., Rull, J., Dies, H., et al. (1985). Nortriptyline and fluphenazine in the symptomatic treatment of diabetic neuropathy. A double-blind cross-over study. PAIN, 23(4), 395–400. https://doi.org/10.1016/0304-3959(85)90010-7
  27. Ha, H., & Gonzalez, A. (2019). Migraine Headache Prophylaxis. American Family Physician, 99(1), 17–24. https://www.aafp.org/pubs/afp/issues/2019/0101/p17.html
  28. Hashemzadeh, S., Mortazavi, M., & Abdi Dezfouli, R. (2024). Quantitative analysis of nortriptyline's analgesic properties: a comparative systematic review and meta-analysis. BMJ Open, 14(8), e085438. https://doi.org/10.1136/bmjopen-2024-085438
  29. Hasler, G. (2010). Pathophysiology of depression: Do we have any solid evidence of interest to clinicians? World Psychiatry, 9(3), 155–161. https://doi.org/10.1002/j.2051-5545.2010.tb00298.x
  30. Haviv, Y., Rettman, A., Aframian, D., et al. (2015). Myofascial pain: an open study on the pharmacotherapeutic response to stepped treatment with tricyclic antidepressants and gabapentin. Journal of Oral & Facial Pain and Headache, 29(2), 144–151. https://doi.org/10.11607/ofph.1408
  31. Hirschfeld, R. M. A. (1999). Efficacy of SSRIs and Newer Antidepressants in Severe Depression. The Journal of Clinical Psychiatry, 60(5), 326–335. https://doi.org/10.4088/jcp.v60n0511
  32. Ho, D. (2005). Antidepressants and the FDA's Black-Box Warning: Determining a Rational Public Policy in the Absence of Sufficient Evidence. AMA Journal of Ethics, 14(6), 483–488. https://doi.org/10.1001/virtualmentor.2012.14.6.pfor2-1206.
  33. How to Spot the Top Warning Signs of a Stroke. (2024, May 17). Rupa Health. https://www.rupahealth.com/post/how-to-spot-the-top-warning-signs-of-a-stroke
  34. Hughes, J., Stead, L., & Lancaster, T. (2005). Nortriptyline for smoking cessation: A review. Nicotine & Tobacco Research, 7(4), 491–499. https://doi.org/10.1080/14622200500185298
  35. Kovich, H., Kim, W., & Quaste, A. M. (2023). Pharmacologic Treatment of Depression. American Family Physician, 107(2), 173–181. https://www.aafp.org/pubs/afp/issues/2023/0200/pharmacologic-treatment-of-depression.html
  36. Kresge, K. (2022, April 6). 9 Common Things That May Be Causing Your Constipation. Rupa Health. https://www.rupahealth.com/post/a-functional-medicine-approach-to-treating-constipation
  37. Kresge, K. (2023, February 21). An Integrative Medicine Approach to Depression. Rupa Health. https://www.rupahealth.com/post/an-integrative-medicine-approach-to-depression
  38. Lab Tests for Patients with Erectile Dysfunction. (2024, October 25). Rupa Health. https://www.rupahealth.com/post/lab-tests-for-patients-with-erectile-dysfunction
  39. Maholy, N. (2023, February 17). A functional medicine approach to anxiety: Testing, nutrition, & supplements. Rupa Health. https://www.rupahealth.com/post/a-functional-medicine-approach-to-anxiety
  40. McCracken, L. M., Yu, L., & Vowles, K. E. (2022). New generation psychological treatments in chronic pain. BMJ, 376(376), e057212. https://doi.org/10.1136/bmj-2021-057212
  41. Menza, M., Dobkin, R. D., Marin, H., et al. (2009). A controlled trial of antidepressants in patients with Parkinson's disease and depression. Neurology, 72(10), 886–892. https://doi.org/10.1212/01.wnl.0000336340.89821.b3
  42. Merwar, G., Gibbons, J. R., Hosseini, S. A., et al. (2020). Nortriptyline. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK482214/
  43. Mirtazapine (Oral Route). Mayo Clinic. https://www.mayoclinic.org/drugs-supplements/mirtazapine-oral-route/description/drg-20067334
  44. Moraczewski, J., Awosika, A. O., & Aedma, K. K. (2022). Tricyclic Antidepressants. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK557791/
  45. Nierenberg, A. A., Papakostas, G. I., Petersen, T., et al. (2003). Nortriptyline for treatment-resistant depression. The Journal of Clinical Psychiatry, 64(1), 35–39. https://doi.org/10.4088/jcp.v64n0108
  46. Nijs, J., Malfliet, A., Roose, E., et al. (2024). Personalized Multimodal Lifestyle Intervention as the Best-Evidenced Treatment for Chronic Pain: State-of-the-Art Clinical Perspective. Journal of Clinical Medicine, 13(3), 644. https://doi.org/10.3390/jcm13030644
  47. NORTRIPTYLINE HYDROCHLORIDE capsule. (2025). DailyMed; National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7b4a3438-57b4-4d88-9843-cc9da529f6f2
  48. PamelorTM. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/018012s029,018013s061lbl.pdf
  49. Reeves, R. R., & Ladner, M. E. (2010). Antidepressant-Induced Suicidality: An Update. CNS Neuroscience & Therapeutics, 16(4), no-no. https://doi.org/10.1111/j.1755-5949.2010.00160.x
  50. Revicki, D. A., Simon, G. E., Chan, K., et al. (1998). Depression, health-related quality of life, and medical cost outcomes of receiving recommended levels of antidepressant treatment. The Journal of Family Practice, 47(6), 446–452. https://pubmed.ncbi.nlm.nih.gov/9866670/
  51. Reynolds, C. F. 3rd, Frank, E., Perel, J. M., et al. (1992). Combined pharmacotherapy and psychotherapy in the acute and continuation treatment of elderly patients with recurrent major depression: a preliminary report. American Journal of Psychiatry, 149(12), 1687–1692. https://doi.org/10.1176/ajp.149.12.1687
  52. Reynolds, C. F., Miller, M. D., Pasternak, R. E., et al. (1999). Treatment of bereavement-related major depressive episodes in later life: a controlled study of acute and continuation treatment with nortriptyline and interpersonal psychotherapy. The American Journal of Psychiatry, 156(2), 202–208. https://doi.org/10.1176/ajp.156.2.202
  53. Sanabria‐Mazo, J. P., Colomer-Carbonell, A., Fernández-Vázquez, Ó., et al. (2023). A systematic review of cognitive behavioral therapy-based interventions for comorbid chronic pain and clinically relevant psychological distress. Frontiers in Psychology, 14. https://doi.org/10.3389/fpsyg.2023.1200685
  54. Song, S. A., Choksawad, K., & Franco, R. A. (2020). The Effectiveness of Nortriptyline and Tolerability of Side Effects in Neurogenic Cough Patients. Annals of Otology, Rhinology & Laryngology, 130(7), 781–787. https://doi.org/10.1177/0003489420970234
  55. Sweetnich, J. (2023, April 17). A Functional Medicine Protocol for Low Libido in Men. Rupa Health. https://www.rupahealth.com/post/a-functional-medicine-protocol-for-low-libido-in-men
  56. Takano, H., Arakawa, R., Nogami, T., et al. (2013). Norepinephrine transporter occupancy by nortriptyline in patients with depression: a positron emission tomography study with (S,S)-[18F]FMeNER-D2. The International Journal of Neuropsychopharmacology, 17(04), 553–560. https://doi.org/10.1017/s1461145713001521
  57. Tricyclic Antidepressant Agent. ScienceDirect. https://www.sciencedirect.com/topics/chemistry/tricyclic-antidepressant-agent
  58. Tricyclic antidepressants. (2022, March 30). Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/depression/in-depth/antidepressants/art-20046983
  59. Understanding psychotherapy and how it works. (2023, December 12). American Psychological Association. https://www.apa.org/topics/psychotherapy/understanding
  60. Warner, C. H., Bobo, W., Warner, C., et al. (2006). Antidepressant Discontinuation Syndrome. American Family Physician, 74(3), 449–456. https://www.aafp.org/pubs/afp/issues/2006/0801/p449.html
  61. Watson, C. P., Vernich, L., Chipman, M., et al. (1998). Nortriptyline versus amitriptyline in postherpetic neuralgia. Neurology, 51(4), 1166–1171. https://doi.org/10.1212/wnl.51.4.1166
  62. Weinberg, J. L. (2023, September 18). Integrative Dermatology Approach to Urticaria (Hives). Rupa Health. https://www.rupahealth.com/post/integrative-dermatology-approach-to-urticaria-hives
  63. Yang, S., & Chang, M. C. (2019). Chronic Pain: Structural and Functional Changes in Brain Structures and Associated Negative Affective States. International Journal of Molecular Sciences, 20(13), 3130. https://doi.org/10.3390/ijms20133130
Order from 30+ labs in 20 seconds (DUTCH, Mosaic, Genova & More!)
We make ordering quick and painless — and best of all, it's free for practitioners.

Latest Articles

View more on Medication Fact Sheets
Subscribe to the magazine for expert-written articles straight to your inbox
Join the thousands of savvy readers who get root cause medicine articles written by doctors in their inbox every week!
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Are you a healthcare practitioner?
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Subscribe to the Magazine for free to keep reading!
Subscribe for free to keep reading, If you are already subscribed, enter your email address to log back in.
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Are you a healthcare practitioner?
Thanks for subscribing!
Oops! Something went wrong while submitting the form.

Hey practitioners! 👋 Join Dr. Chris Magryta and Dr. Erik Lundquist for a comprehensive 6-week course on evaluating functional medicine labs from two perspectives: adult and pediatric. In this course, you’ll explore the convergence of lab results across different diseases and age groups, understanding how human lab values vary on a continuum influenced by age, genetics, and time. Register Here! Register Here.